Legis Daily

To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes.

USA115th CongressHR-5568| House 
| Updated: 4/18/2018
Frank Pallone

Frank Pallone

Democratic Representative

New Jersey

Cosponsors (1)
Brett Guthrie (Republican)

Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2018 This bill authorizes the Food and Drug Administration to partner with institutions of higher education to designate them as National Centers of Excellence in Continuous Pharmaceutical Manufacturing for the purpose of studying and recommending improvements to the process of continuous manufacturing of medications. (Currently, most medications are manufactured in batches.)
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 18, 2018
Introduced in House
Apr 18, 2018
Referred to the House Committee on Energy and Commerce.
  • April 18, 2018
    Introduced in House
  • April 18, 2018
    Referred to the House Committee on Energy and Commerce.

Health

Advanced technology and technological innovationsCongressional oversightDrug safety, medical device, and laboratory regulationEducational facilities and institutionsGovernment information and archivesHealth programs administration and fundingHealth technology, devices, suppliesHigher educationManufacturingPrescription drugsProduct development and innovationResearch administration and fundingResearch and development

To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing, and for other purposes.

USA115th CongressHR-5568| House 
| Updated: 4/18/2018
National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2018 This bill authorizes the Food and Drug Administration to partner with institutions of higher education to designate them as National Centers of Excellence in Continuous Pharmaceutical Manufacturing for the purpose of studying and recommending improvements to the process of continuous manufacturing of medications. (Currently, most medications are manufactured in batches.)
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 18, 2018
Introduced in House
Apr 18, 2018
Referred to the House Committee on Energy and Commerce.
  • April 18, 2018
    Introduced in House
  • April 18, 2018
    Referred to the House Committee on Energy and Commerce.
Frank Pallone

Frank Pallone

Democratic Representative

New Jersey

Cosponsors (1)
Brett Guthrie (Republican)

Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Advanced technology and technological innovationsCongressional oversightDrug safety, medical device, and laboratory regulationEducational facilities and institutionsGovernment information and archivesHealth programs administration and fundingHealth technology, devices, suppliesHigher educationManufacturingPrescription drugsProduct development and innovationResearch administration and fundingResearch and development